The Problem: There are many types of viral hepatitis and thanks to vaccines and medicines is more preventable and treatable than ever before. There is a gap, however, between the opportunities for prevention and treatment and those practices within health care. In addition, there is a need for new vaccines for types of hepatitis that are currently not preventable. There is also a need for better medicines that are more effective and with fewer side effects.
Our Engagement: We were engaged to help a coalition of hepatitis A, B and C organizations to facilitate their collaborative efforts to eliminate viral hepatitis in the US.
Our Actions: We facilitated meetings that resulted in the formation of the National Viral Hepatitis Roundtable, a major national meeting of stakeholders and the design of an agenda to accomplish their mission. We assisted in the steps to raise more than $1.1 million in grant funds and $1.5 million in in-kind resources. We developed the report presented by the NVHR to Congress.